Thalidomide
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
vorinostat
HDAC inhibitor · Antineoplastic agent
HDAC inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactions
- ThalidomideSevereDatabaseDDInter
- Valproic AcidSevereDatabaseDDInter
Mechanism
Vorinostat binds to the active site of HDACs and chelates zinc ions in the active site. The resulting inhibition of HDACs causes the accumulation of acetylated histones and other acetylated proteins, among which are transcription factors crucial for cell differentiation. It inhibits the enzymatic activities of HDAC1, -2, and -3 (class I) and HDAC6 (class II).
Indications
cutaneous T-cell lymphoma with persistent or recurrent disease after two systemic therapies
Pharmacokinetics
Half-life
about 2 h (elimination)
Bioavailability
slightly improved when taken with a meal
Metabolism
glucuronidation and hydrolysis (mostly)
Side effects
Common
diarrheafatiguenauseathrombocytopeniaanorexiadysgeusia
Pregnancy & lactation
Pregnancy
D
Drug interactions
Valproic Acid
Severe
Database
Clinical effect not specified
Source: DDInter
10 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Coeliac disease
OTHER · Gastroenterology · 2016
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Systemic lupus erythematosus
EULAR · Rheumatology · 2023
Other HDAC inhibitor drugs
Ask House about vorinostat
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team